SRR615515
GTEX
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- GTEX
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- GTEX
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- KRAS_SIGNALING_DN+0.459
- INFLAMMATORY_RESPONSE+0.391
- ANGIOGENESIS+0.362
- IL6_JAK_STAT3_SIGNALING+0.311
- ALLOGRAFT_REJECTION+0.303
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.303
- COAGULATION+0.257
- MYOGENESIS+0.244
- SPERMATOGENESIS+0.211
- APICAL_SURFACE+0.203
Top 10 suppressed
- OXIDATIVE_PHOSPHORYLATION-0.700
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.580
- MYC_TARGETS_V1-0.567
- DNA_REPAIR-0.550
- PROTEIN_SECRETION-0.538
- UNFOLDED_PROTEIN_RESPONSE-0.490
- MTORC1_SIGNALING-0.488
- ADIPOGENESIS-0.476
- MYC_TARGETS_V2-0.473
- PEROXISOME-0.428
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR1328035 | GTEX | — | 0.979 |
| 2 | SRR661433 | GTEX | — | 0.975 |
| 3 | SRR1475803 | GTEX | — | 0.967 |
| 4 | SRR1485167 | GTEX | — | 0.965 |
| 5 | SRR1358689 | GTEX | — | 0.962 |
| 6 | SRR1443979 | GTEX | — | 0.961 |
| 7 | SRR658188 | GTEX | — | 0.959 |
| 8 | SRR1487295 | GTEX | — | 0.957 |
| 9 | SRR1436966 | GTEX | — | 0.955 |
| 10 | SRR1338301 | GTEX | — | 0.955 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 19 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| KRAS_SIGNALING_DN | 0.459 | Remibrutinib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.391 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.362 | Remibrutinib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.311 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.303 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.303 | Inavolisib | — uncovered |
| COAGULATION | 0.257 | Binimetinib | — uncovered |
| MYOGENESIS | 0.244 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.211 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.203 | Temsirolimus | — uncovered |
| KRAS_SIGNALING_UP | 0.190 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.170 | Cobimetinib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.155 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.138 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.085 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.080 | Idelalisib | — uncovered |
| COMPLEMENT | 0.049 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.035 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.028 | Inavolisib | — uncovered |